| 苏东旭,李晓轩.康复新液联合利多卡因辅以氧疗治疗复发性口腔溃疡疗效分析[J].中国烧伤创疡杂志,2022,(1):12~15. |
| DOI： |
| 中文关键词: 复发性口腔溃疡 康复新液 利多卡因 氧疗 白细胞介素-６ 肿瘤坏死因子-α |
| 英文关键词:Recurrent oral ulcers Kangfuxin Solution Lidocaine Oxygen therapy Interleukin-6 Tumor necrosis factor-α |
| 基金项目: |
|
| 摘要点击次数: 1753 |
| 全文下载次数: 4846 |
| 中文摘要: |
| 【摘要】 目的 观察分析康复新液联合利多卡因辅以氧疗治疗复发性口腔溃疡的临床效果。 方法 选取2019年10月至2020年10月焦作市五官医院收治的108 例复发性口腔溃疡患者作为研究对象，并按照随机数表法将其随机分为研究组与常规组，每组54例，常规组患者予以利多卡因联合氧疗治疗，研究组患者在常规组治疗的基础上联合应用康复新液治疗， 对比两组患者白细胞介素-6(IL-6) 及肿瘤坏死因子-α(TNF-α)水平变化情况、视觉模拟评分法(VAS) 评分变化情况、临床疗效、溃疡创面愈合时间以及复发情况。结果 治疗第3天，研究组患者IL-6、TNF-α水平及VAS评分均明显低于常规组(t=26.420、9.653、5.831，P均＜0.001），临床疗效明显优于常规组 (Z = - 2.026，P = 0.043）；研究组患者溃疡创面愈合时间明显短于常规组 ( t = 8.204，P＜0.001）；随访 6 个月，研究组患者复发率明显低于常规组(χ2 = 5.939，P = 0.015）。结论 康复新液联合利多卡因辅以氧疗治疗复发性口腔溃疡，可有效减轻局部炎症反应及疼痛程度， 缩短溃疡创面愈合时间， 疗效显著，且复发率更低。 |
| 英文摘要: |
| 【Abstract】 Objective To observe the clinical efficacy of Kangfuxin Solution combined with Lidocaine supplemented by oxygen therapy in the treatment of recurrent oral ulcers. Methods 108 patients with recurrent oral ulcers， admittedto Jiaozuo ENT Hospital from October 2019 to October 2020 were enrolled as the subjects of research and divided into a study group (n =54) and a conventional group (n = 54). Patients in conventional group were treated with Lidocaine in combination with oxygen therapy， whereas patients in study group were treated with Kangfuxin Solution in combination with Lidocaine and oxygen therapy. The changes of interleukin-6 (IL-6 better than conventional group (Z = -2.026， P =0.043)， and the healing time of ulcer wounds in study group was much shorter than conventional group (t = 8.204， P < 0.001). 6-month follow-up showed that the recurrence rate of ulcers in study group was significantly lower than conventional group (χ2 = 5.939， P = 0.015). Conclusion Kangfuxin Solution combined with Lidocaine supplemented by oxygen therapy in the treatment of recurrent oral ulcers can effectively relieve local inflammation and pain， shorten the healing time of ulcer wounds， and realize remarkable clinical efficacy with a much low recurrence rate. |
|
